Table 1.

Changes in AP waveform properties across the course of recording

	ΔVm (mV)	ΔVthreshold (mV)	ΔAP half-width (% baseline)	ΔAP peak (mV)	Δ rheobase (pA)	n	Baseline EPSP (mV)	Postdrug EPSP (mV)
Time-locked control (15 min)	0.48 ± 1.05	−1.34 ± 1.86	98 ± 10	−3.23 ± 5.43	−10 ± 29.21	35	5.9 ± 4.6	4.6 ± 3.8
Conotoxin MVIIC	0.47 ± 0.54	−2.12 ± 1.55	99 ± 8	−3.12 ± 2.97	−21.43 ± 26.73	8	4.8 ± 3.8	0.5 ± 0.4*
SNX-482	−0.18 ± 0.72	−0.92 ± 1.00	102 ± 11	−3.39 ± 5.00	−14.29 ± 19.67	8	—	—
TTA-P2	0.37 ± 0.65	−0.90 ± 0.88	100 ± 8	−3.02 ± 2.75	7.50 ± 37.36	11	—	—
Nifedipine	0.89 ± 0.42	−0.62 ± 1.42	102 ± 5	−3.12 ± 3.00	−8.33 ± 25.82	5	—	—
Conotoxin GVIA	0.14 ± 0.90	−0.78 ± 1.46	103 ± 5	−2.64 ± 1.17	−20.00 ± 20.92	5	5.3 ± 6.0	4.8 ± 5.5
Agatoxin TK	0.55 ± 0.42	−2.55 ± 0.84	104 ± 8	−2.70 ± 1.71	−12.50 ± 13.69	6	5.6 ± 4.1	1.5 ± 1.4*
Ryanodine	1.49 ± 4.24	−1.14 ± 1.60	106 ± 11	−5.38 ± 5.62	−13.46 ± 24.19	14	—	—
Nickel(II) chloride	−0.26 ± 3.09	−0.51 ± 2.34	102 ± 5	−2.54 ± 2.58	−33.33 ± 43.78	6	—	—
Time-locked control (25 min)	0.54 ± 0.87	−3.25 ± 2.37	101 ± 7	−5.16 ± 3.71	−37.50 ± 37.91	6	3.7 ± 2.4	2.1 ± 0.8
CaV antagonist cocktail	0.37 ± 0.83	−3.26 ± 2.96	105 ± 4	−2.58 ± 6.08	−45.00 ± 32.60	5	2.5 ± 1.5	0.5 ± 0.4*
S1 time-lock control	0.46 ± 0.96	−3.09 ± 2.07	96 ± 4	−2.57 ± 1.68	−8.33 ± 14.43	3	7.8 ± 2.5	7.2 ± 2.8
S1 conotoxin MVIIC	0.58 ± 2.57	−1.04 ± 1.84	98 ± 7	−6.09 ± 5.48	0 ± 86.60	3	6.0 ± 3.0	0.7 ± 0.4*

*p < 0.05. One-way ANOVAs or two-tailed t tests were performed for each waveform property, as appropriate. Paired t tests were performed for EPSP amplitudes.